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Abstract
Malassezia pachydermatis is recognized as a normal inhabitant and an
opportunistic pathogen of the external ear canal and skin of dogs
and cats. In special clinical conditions, and mainly in the cases of
therapeutic failure related to external otitis and dermatitis complicated
by this yeast, is recommended testing susceptibility to antifungal drugs.
Different approaches of evaluating the susceptibility of yeasts faced
to antifungals in laboratory exist, some of them are commercial
approaches and others previously standardized by the CLSI (NCCLS,
2002).  The purpose of this study was to evaluate the susceptibility
of 17 samples of M. pachydermatis from canine external otitis using
two different in vitro antifungal susceptibility methods: the Etest®
and the broth Microdilution Method (MD) with ketoconazole. The
mean MIC observed between the 17 samples were 0.103mg/mL to
ETEST and 0.0012mg/mL to MD ranging from 0.004 to 0.75mg/
mL in ETEST and 0.0019 and 0.03mg/mL in MD using the same
samples.  By ETEST, two (11.8%) samples were resistant, eight
(47.1%) susceptible and seven (41.1%) showed intermediate
susceptibility. Through the MD it was observed four (23.5%) resistant
samples, seven (41.2%) susceptible and six (35.3%) samples with
intermediate susceptibility.  Despite of  the percentages being equivalent
in each rank of susceptibility through the two techniques, the results
do not correspond to the same sample.  These results showed that
there is an urgent need to standardize those values considered as
parameters for growth inhibition of this yeast. Then a simple and







The interest by the stardandization of
the susceptibility tests to antifungals is
relatively recent. The development of
susceptibility tests to antimicrobials has its
history linked to the advancements obtained
in the antibacterial therapy. With the advent
of new chemotherapics, antibiotics and the
recognition of resistant bacteria to the
penicillin, microbiology laboratories passed
it carry out tests of  sensitivity.1 There are two
decades, new therapeutic options have being
developed and there are fungi resistance,
mainly in the yeasts of the genus Candida to
the drugs commercially available.2,3  Due the
tests used for in vitro evaluation of the
antifungal activity was the same used in the
evaluation of  antibacterial activity, usually, the
same techniques are developed: broth
dilution, agar dilution and agar diffusion. The
final reading of the tests of dilution in liquid
and/or solid is going to identify the smaller
concentration of the drug that inhibits the
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growth of the microorganism studied.
Recently the National Committee Clinical
Laboratory Standards4, nowadays known as
Clinical and Laboratory Standards Institute
(CLSI), defined two standardized
approaches of broth Microdilution as
antifungal tests, the M27A2 and the M38P,
to some yeasts and fungi filamentous
respectively.  The NCCLS4 recommends the
use of the RPMI 1640 in the achievement
of antifungal susceptibility testing with yeasts
(Candida spp. and Cryptococcus spp.), despite
of not to have been used in yeasts of the
genus Malassezia5.  Others authors6,7 used to
the same technique of broth Microdilution,
but with Sabouraud dextrose, obtaining better
growth of the yeast. However, this is not a
routine procedure technique in the
laboratory.8 The ETEST method (agar
diffusion) was introduced in 1988 as an
alternative for determination of  the MIC,
being used mainly to confirm the resistance
to the antimicrobials. In Brazil, only in 1997,
the first study was carried out about
antifungal susceptibility testing of M.
pachydermatis, with the ETEST method.9,10
The ketoconazole is the imidazol
more used until now and it presents elevated
efficacy against agents of systemic and
superficial mycoses.11,12 It includes Malassezia
and others dermatophytes, resistant or not
resistant to griseofulvina, to several agents
of systemic mycoses, detaching their
purpose in the paracoccidioidomicosis and
histoplasmosis treatmen.11,13 It was the first
antifungal substance used orally in the
systemic mycoses treatments and up to date,
is used in non and dermatological mycoses
in the veterinary small animals, mainly due
to the short value.13,14
Malassezia pachydermatis is recognized
as a normal inhabitant and an opportunistic
pathogen from the external ear channel and
skin of dogs and cats, being considered one
of the most frequent microorganisms
associated with external otitis in dogs by
several authors. This yeast also can be found
in the rectum, interdigital, anal sacs and
vagina.  In the last years, some investigations
also pointed out this yeast as cause of canine
dermatitis.15,16, 17,18,19,20,21,22,23,24,25,26,27
The purpose of this study was to
evaluate the antifungal susceptibility of 17
isolates of M. pachydermatis to ketoconazole
using two antifungal susceptibility methods.
Material and Method
The NCCLS’ broth microdilution
method (CLSI)4 recommendations were
adapted to M. pachydermatis by Eichenberg
et al.6 and Nascente et al.7. Ten dilutions of
the drug storage solution were prepared
obtaining 10 solutions with a gradient 10
times greater than the final solution of each
drug used. The ten solutions obtained this
way had the drug concentration from
0.0000574 to 0.03mg/mL to ketoconazole
and they were put into the first 10 contiguous
wells of a sterile microtiter plate. The solution
containing each sample of yest was
transferred in aliquots of 100µL into each
of the sterile plates that previously had
100µL of the solution containing the
antifungal drug tested. The wells 11 and 12
had the positive control (100µL of
Sabouraud dextrose agar and 100µL of the
half-inoculum solution) and the negative
control (200µl of the same culture medium),
respectively. The plates were incubated at
37°C for 72 hours. The readings were made
by visual comparison of the yeast growth
into the wells one to ten with wells that had
the positive control (wells 11). The lowest
concentration that produced a relative
significant inhibition (around 50%) of
the yeast growth compared to the
positive control was identified as the MIC
(Minimum Inhibitory Concentrations) of the
drug (10, 11).
The strips of the Etest® have a defined
and consistent gradient of the antifungal drug
(0.002 to 32.0µg/mL of ketoconazole
allowing a quantitative reading. The culture
medium used was Sabouraud dextrose agar
with chloramphenicol according to the Etest®
manufacturer´s recommendations. M.
pachydermatis samples were suspended in
saline with turbidity adjusted to level 1 of
the McFarland scale and cultivated by
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spreading the sample in the culture medium.
After 15 minutes, the strips were distributed
over the medium and incubated at 37°C.
The readings were performed at 48hours
and the the lowest concentration (MICs)
of  the drug was determined by the Etest®
strip pattern.
The comparison of the results was
carried out with the 17 samples of M.
pachydermatis tested.  The MICs were
calculated according to Coutinho and Paula9
for the Etest® and Eichenberg et al.6 for the
broth microdilution method. M. pachydermatis
was classified as susceptible (S), intermediary
susceptible (I) and resistant (R) using the
criteria: S = MIC sample ≤ MIC50, I =
MIC50 < MIC sample ≤ MIC90, R = MIC
sample > MIC90.
Results and Discussion
The MICs averages observed
between the 17 samples evaluated
simultaneously with ketoconazole and using
the two methodologies were 0.103mg/mL
to ETEST and 0.0012mg/mL to Broth
Microdilution.  The mean MIC presented
difference between the two methods, ranging
from 0.004 to 0,75mg/mL in the ETEST and
from 0.0019 to 0.03mg/mL in BM, using the
same M pachydermatis samples.
Comparing the results obtained with
the two methodologies, it can be possible
to observe that by the ETEST, two (11.8%)
samples were resistant, eight (47.1%)
susceptible and seven (41.1%) samples
presented intermediate susceptibility. Using
the BM method, it was observed four
(23.5%) resistant samples, seven (41.2%)
susceptible ones and six (35.3%) samples
with intermediate susceptibility front the
same drug.  However, despite the
percentages being similar in each rank of
susceptibility based on the two methods
studied, the results do not correspond to the
same for each sample, as can be observed
in the table 1.
Considering the samples with similar
results (S, I, R) in the both methodologies
tested, it was observed an agreement in six
(35.3%) samples.  Four samples with
corroborating results were susceptible and
two presented intermediate susceptibility
(Table 1).
Independently of the method chosen
for the determination of  the antifungal MIC,
different conditions of achievement of the
test alter the final results23.  Galgiane et al.28
and Calhoum et al.29 showed that the
variability of MIC results obtained with
anphotericin B, flucitosin and ketoconazole
for yeasts studied in different conditions,
should not be accepted; such  difference was
attributed to the absence of standardization
of the method and the factors recognized
as responsible for this variability of the results
obtained in different laboratories such as:
composition of the cultivation medium, pH,
time and temperature of inoculation, size of
the inoculum and reading criteria4. The culture
medium employed in methods of
susceptibility to antimicrobials should be
capable of support an adequate growth of
the microorganisms without, however,
because any interaction with the activities of
the drugs used in the study.30
Table 1 - Susceptibility to ketoconazole in Microdilution broth technique and ETEST front 17 M. pachydermatis
isolates from ear canal of dogs obtained in the Faculdade de Veterinária (UFPel) in 2007
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Nascente et al.7 observed that KTZ
MICs for Etest® ranged from 0.002 to
0.25mg/mL and the MIC average was
0.057mg/mL. The broth microdilution
method showed a MIC ranging from 0.03
to 8mg/mL and a MIC average of
1.28mg/mL. The MIC results of the Etest®
obtained in this study had a wide range of
higher values and an average MIC higher than
that reported by Coutinho and Paula9. These
authors9 found a MIC average of 0.08mg/
mL (0.015 to 0.25 mg/mL) and MIC values
lower than the data obtained by Uchida,
Nakade and Kitazawa31 that ranged from
0.002mg/mL to 10mg/mL, but similar to
the values obtained by Lorenzini, Mercantini
and Bernardis32 and Mickelsen et al.33.
The concentrations of the antifungal
drugs tested were different for each of the
two techniques and for this reason it was
not possible to estimate whether there was
a coincidence in the MICs found in each of
the tests alone. It was possible to establish
relations between the values just after
classifying the yeast isolates in susceptible,
intermediary susceptible, and resistant using
the susceptibility calculation (Table 1).
The differences between the methods
did not allow an analysis-in-depth of the
results because the MIC test is highly
dependent of factors such as the inoculum
concentration, chemical composition of the
medium, pH, temperature, and incubation
time.6,7,16,28,30,34 The results found in this work
showed that it is possible to compare the
degree of susceptibility to each antifungal
drug but without compare the MICs. To
compare the MIC values, it is necessary an
agreement for the drug concentrations to be
tested in both methods because the Etest®
have a broader range for drug concentrations
than the broth Microdilution test.
Conclusion
The aspects related to the different
methods indicate the necessity of a
standardized method that could be widely
used in research and in mycology
laboratories as in the same manner as in
bacteriology. More studies about the MICs
of M. pachydermatis are necessary to
standardize the values for growth inhibition
of the yeast in both methods, allowing
comparisons of results obtained from
different laboratories.
Comparação da técnica de microdiluição em caldo e ETEST para o
cetoconazol frente à Malassezia pachydermatis
Resumo
Malassezia pachydermatis é reconhecida como um habitante normal e
patógeno oportunista do meato acústico externo e da pele de cães e
gatos. Em condições clínicas especiais e em casos de falha terapêutica
relatada em otite externa e dermatite complicada por esta levedura, é
recomendado o teste de suscetibilidade antifúngica. Existem diferentes
métodos de avaliação da suscetibilidade da levedura frente a
antifúngicos em laboratório, alguns métodos comerciais e outros
previamente padronizados pelo CLSI (NCCLS, 2002).  O objetivo
deste estudo foi o de avaliar a suscetibilidade de 17 amostras de M.
pachydermatis proveniente de otite externa canina por meio de duas
técnicas in vitro de antifungigramas: o Etest® e a microdiluição em
caldo (MC) com o cetoconazol. A media da Concentração Inibitória
Mínima (CIM) observada entre as 17 amostras foram 0.103mg/mL
para o ETEST e 0.0012mg/mL para a  MC variando de 0.004 a
0.75mg/mL no ETEST e entre 0.0019 e 0.03mg/mL na MC usando
as mesmas amostras. Pelo ETEST, duas (11.8%) amostras foram
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sensibilidade intermediária. Na MC foram observadas quatro (23.5%)
amostras resistentes, sete (41.2%) sensíveis e seis (35.3%) amostras
com sensibilidade intermediária.  Apesar das porcentagens de
sensibilidade serem semelhantes pelas duas técnicas, os resultados de
CIM não correspondem na uma mesma amostra. Estes resultados
mostraram que há uma urgente necessidade de padronização dos
valores considerados como parâmetros para inibição do crescimento
da levedura. Portanto, um método simples e eficiente deveria ser
usado rotina na prática de laboratório.
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